(AOF) – Spineway totals a turnover of 2.1 million euros for the 3rd quarter of 2023, compared to 2.24 million in 2022, a drop of 8%. This brings 9-month activity to 7.5 million euros, an increase of 40% compared to last year. The specialist in ranges of implants and innovative surgical ancillaries (instruments) intended to treat severe spinal pathologies specifies that the increase in sales over 9 months is driven by the sales of Spine Innovations, integrated in July 2022.
The turnover for the 3rd quarter is “mechanically marked by a less favorable scope effect” underlines the group.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.